Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CLYM vs CVM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLYM Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–2 Matrix Metrics)

CLYM Overall Winner 6-Pillar Tally: CLYM 3 – 2 CVM (1 Tie) Matrix Metrics: CLYM 6 – 2 CVM

As of Nov 17, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CLYM carries a Unified Composite Score of 45.7/100 (HOLD) at $9.78 (N/M Forward P/E, 0.0% operating margin), whereas CVM carries 43.5/100 (HOLD) at $1.85 (23.0x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: CLYM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4); meanwhile CVM is in a Breakdown options structure phase (RSI 61.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CLYM vs CVM
CLYM NASDAQ Head-to-Head Winner
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.78
-1.61% 1D
Market Cap $608.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.52β · 112% Vol
Unified Composite Score
45.7 / 100 HOLD
Tech 41.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.4%), weak momentum, RSI 43
RSI-14: 43.4 · SMA20: $10.22 · SMA50: $11.34
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.85
+11.45% 1D
Market Cap $22.5M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.42β · 140% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 61.8 · SMA20: $1.48 · SMA50: $1.67

6-Pillar Scorecard Institutional Category Breakdown (CLYM 3 – 2 CVM)

Columns: Metric · CLYM · CVM
1. Valuation Multiples CVM
Forward P/E N/M 23.0x
Trailing P/E N/M 23.0x
PEG Ratio N/M 1.12x
EV / Revenue N/M N/M
2. Growth & Scale CLYM
Revenue Growth (YoY) +0.0% -62.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $28,558
Market Cap $608.5M $22.5M
3. Profitability & Quality CLYM
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -29.3% -252.5%
4. Balance Sheet & Cash Flow CVM
Cash Generation (TTM) N/A -$17M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.95 Book/Sh · -29.3% ROE $6.6M Net Debt (1.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CLYM
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CLYM (6) vs CVM (2)
Institutional Metric CLYM CVM Criterion Row Edge
Market Capitalization
Scale
$608.5M $22.5M Larger Scale CLYM
Trailing P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Forward P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Revenue Growth (YoY)
Growth
+0.0% -62.7% Higher Growth CLYM
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-29.3% -252.5% Higher ROE CLYM
52-Week Range Position
Momentum
49% ($2–$18) 14% ($1–$8) Stronger Trend CLYM
Beta / 30D Volatility
Risk Regime
1.52β · 112% Vol 0.42β · 140% Vol Lower Realized Risk CLYM
Unified Institutional Score
Composite Signal
45.7 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite CLYM
Trailing 12M Revenue (USD)
Operating Scale
N/A $28,558 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.12x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($3.95 Book/Sh · -29.3% ROE) -$17M ($6.6M Net Debt (1.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CVM +11.61 pp
CLYM: +0.51% · CVM: +12.12%
3M Horizon CVM +56.4 pp
CLYM: -43.6% · CVM: +12.8%
6M Horizon CVM +15.0 pp
CLYM: +1.35% · CVM: +16.35%
1Y Horizon CLYM +486.79 pp
CLYM: +414.74% · CVM: -72.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs CVM. Trailing 12-month operating profitability (CLYM 0.0% vs CVM 0.0%) and valuation multiples (CLYM N/M vs CVM 23.0x Forward P/E) are benchmarked directly in Pillar 4 below.

CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M
CVM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28,558
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-252.5% · 23.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $608.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $22.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CLYM vs CVM Key Questions & Quantitative Answers

As of Nov 17, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CLYM carries a Unified Composite Score of 45.7/100 (HOLD) at $9.78 (N/M Forward P/E, 0.0% operating margin), whereas CVM carries 43.5/100 (HOLD) at $1.85 (23.0x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CLYM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4); meanwhile CVM is in a Breakdown options structure phase (RSI 61.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CLYM leads the Growth & Scale pillar: CLYM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CVM at -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CLYM generates N/A in USD-normalized revenue versus $28,558 for CVM. In operating R&D and SG&A reinvestment, CLYM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVM.

CVM screens cheaper on headline valuation multiples. CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLYM (-29.3% ROE) versus CVM (-252.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 112% Vol realized risk). By comparison, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.42β · 140% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.